Explore more at blueowl.com
Credit

Sector Spotlights: Healthcare & Life Sciences

June 26, 2024
Less than 1 min read

Sector Spotlights is a series that features sector experts from our investments teams, who introduce their respective sectors and how they approach their areas of investment. The goal of this series is to provide insight into how Blue Owl views, approaches, and invests in certain sectors. In this installment, we spotlight Healthcare & Life Sciences within Blue Owl Credit. 

 

Meet Blue Owl Credit’s Healthcare & Life Sciences sector experts

Luna McKeon is a Managing Director at Blue Owl and member of the Direct Lending Investment Team. In her role, she focuses on supporting the firm's healthcare direct lending efforts. Sandip Agarwala is a Managing Director at Blue Owl and member of the Direct Lending Investment Team. In his role, he focuses on life sciences credit and royalty investments.

Defining the Healthcare sector at Blue Owl Credit

The Healthcare sector is extremely large and diversified with distinctive, uncorrelated subsectors. Our investment team segments the Healthcare sector into “Products” and “Services”. Healthcare is the second-largest sector within Blue Owl Credit.

Blue Owl Credit’s conviction in Healthcare and Life Sciences Investing

Healthcare has been core sector focus since Blue Owl Credit’s inception in 2016, as it reflects the core investment attributes of our credit thesis: non-cyclical, diversified end markets, and positive macroeconomic tailwinds. Life Sciences is a high conviction sector as it is supported by macroeconomic tailwinds, including: scientific innovations, regulatory environment, and capital markets environment.

How Blue Owl Credit invests in Healthcare and Life Sciences

Our Healthcare direct lending investment team looks for companies that increase access to unmet medical needs, improve patient outcomes, and reduce overall costs. Our Life Sciences Credit & Royalty investment team assesses companies as separate R&D and commercial-stage businesses.

Understanding Royalty Financing in Life Sciences with Blue Owl Credit

Royalties are cash flow streams that are directly tied to the sales of a product. There are two types of royalties: passive royalty and synthetic royalty.

Innovations and investment opportunities in Healthcare and Life Sciences with Blue Owl Credit

Our Healthcare direct lending investment team is excited about opportunities in healthcare technology and alternative reimbursement models. Our Life Sciences Credit & Royalty investment team sees potential for innovations in antibody drug conjugates and radio pharmaceuticals.

 

Past performance is not a guarantee of future results. The views and opinions expressed herein are those of Blue Owl and are subject to change as markets and other conditions fluctuate. Blue Owl is under no obligation to update or keep current the information presented.

Please see endnotes and important information at the end of this page.

Read more from Blue Owl 
Contact Us

Have a question?

Get in touch with a member of our Private Wealth sales team today. Individual Investors, please contact your financial advisor for more information.

Contact us Learn more about Blue Owl

Important information

Unless otherwise indicated, the information referenced herein is as of February 29, 2024.

Past performance is not a guide to future results.

Assets Under Management (“AUM”) refers to the assets that we manage and are generally equal to the sum of (i) net asset value (“NAV”); (ii) drawn and undrawn debt; and (iii) uncalled capital commitments.

The material presented is proprietary information regarding Blue Owl Capital Inc. (“Blue Owl”), its affiliates and investment program, funds sponsored by Blue Owl, including the Blue Owl Credit, GP Strategic Capital Funds and the Real Estate Funds (collectively the “Blue Owl Funds”) as well as investment held by the Blue Owl Funds. 

An investment in the Fund entails a high degree of risk. Prospective investors should consider all of the risk factors set forth in the "Certain Risk Factors and Actual and Potential Conflicts of Interest" of the PPM or Prospectus, each of which could have an adverse effect on the Fund and on the value of Interests. 

An investment in the Fund is suitable only for sophisticated investors and requires the financial ability and willingness to accept the high risks and lack of liquidity associated with an investment in the Fund. Investors in the Fund must be prepared to bear such risks for an indefinite period of time. There will be restrictions on transferring interests in the Fund, and the investment performance of the Fund may be volatile. Investors must be prepared to hold their interests in the Fund until its dissolution and should have the financial ability and willingness to accept the risk characteristics of the Fund's investments. .

There can be no assurances or guarantees that the Fund's investment objectives will be realized, that the Fund's investment strategy will prove successful or that investors will not lose all or a portion of their investment in the Fund. 

Furthermore, investors should not construe the performance of any predecessor funds as providing any assurances or predictive value regarding future performance of the Fund. 

The views expressed and, except as otherwise indicated, the information provided are as of the report date and are subject to change, update, revision, verification, and amendment, materially or otherwise, without notice, as market or other conditions change. Since these conditions can change frequently, there can be no assurance that the trends described herein will continue or that any forecasts are accurate. In addition, certain of the statements contained in this material may be statements of future expectations and other forward-looking statements that are based on the current views and assumptions of Blue Owl and involve known and unknown risks and uncertainties (including those discussed below) that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These statements may be forward-looking by reason of context or identified by words such as “may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue” and other similar expressions. Neither Blue Owl, its affiliates, nor any of Blue Owl’s or its affiliates' respective advisers, members, directors, officers, partners, agents, representatives or employees or any other person (collectively the “Blue Owl Entities”) is under any obligation to update or keep current the information contained in this document.

This material contains information from third party sources which Blue Owl has not verified. No representation or warranty, express or implied, is given by or on behalf of the Blue Owl Entities as to the accuracy, fairness, correctness or completeness of the information or opinions contained in this material and no liability whatsoever (in negligence or otherwise) is accepted by the Blue Owl Entities for any loss howsoever arising, directly or indirectly, from any use of this material or its contents, or otherwise arising in connection therewith.

All investments are subject to risk, including the loss of the principal amount invested. These risks may include limited operating history, uncertain distributions, inconsistent valuation of the portfolio, changing interest rates, leveraging of assets, reliance on the investment advisor, potential conflicts of interest, payment of substantial fees to the investment advisor and the dealer manager, potential illiquidity, and liquidation at more or less than the original amount invested. Diversification will not guarantee profitability or protection against loss. Performance may be volatile, and the NAV may fluctuate.

This material is for informational purposes only and is not an offer or a solicitation to sell or subscribe for any fund and does not constitute investment, legal, regulatory, business, tax, financial, accounting, or other advice or a recommendation regarding any securities of Blue Owl, of any fund or vehicle managed by Blue Owl, or of any other issuer of securities. Only a definitive offering document (i.e.: Prospectus or Private Placement Memorandum) can make such an offer. Neither the Securities and Exchange Commission, the Attorney General of the State of New York nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or Private Placement Memorandum is truthful or complete. Any representation to the contrary is a criminal offense. Securities are offered through Blue Owl Securities LLC, member of FINRA/SIPC, as Dealer Manager.

Copyright© Blue Owl Capital Inc. 2024. All rights reserved. This material is proprietary and may not be reproduced, transferred, or distributed in any form without prior written permission from Blue Owl. It is delivered on an “as is” basis without warranty or liability by accepting the information, you agree to abide by all applicable copyright and other laws, as well as any additional copyright notices or restrictions contained in the information.